The Transformation of Johnson & Johnson From Family Business to Healthcare Giant

Johnson & Johnson is one of the world’s largest healthcare conglomerates, boasting an expansive medical device business, extensive pharmaceutical division and consumer products ranging from Band-Aids to Listerine.

J&J recently made headlines when it announced plans to spin off its consumer healthcare division into an independent publicly listed company called Kenvue, following in the footsteps of other large healthcare firms.

1. Creating a Single Operating Model

What has become one of the largest healthcare companies began as three innovative siblings who came together in 1886. One was an innovative leader, while two others excelled as inventors and marketers – all coming together to form the multibillion dollar enterprise known today as Johnson & Johnson.

Johnson & Johnson made clear from its founding that their primary responsibility lay with physicians, nurses and patients who would use their products. This philosophy led to innovative product improvements such as medicated plasters that allowed people to directly apply treatments directly onto their skin; as well as groundbreaking production methods allowing the company to manufacture sterilized surgical instruments.

James Johnson, Johnson & Johnson’s founder and namesake, insisted that Johnson & Johnson play an active role in its communities through its Credo which remains prominent at headquarters. As such, this dedication has resulted in Johnson & Johnson earning a strong reputation as a trustworthy and responsible corporate citizen.

Johnson & Johnson has always followed a flexible operating model that allows them to expand in whatever way makes sense for their business. This has enabled them to remain at the top of their industry and remain cost-competitive when the economy shifts.

Johnson & Johnson took steps during the pandemic to ensure critical supplies reached hospitals and healthcare professionals quickly, which meant making major adjustments to its typical operations. To facilitate this task, it developed roadmaps outlining what they needed and how it would be completed.

2. Accelerating Innovation

J&J has become one of the largest health care conglomerates worldwide thanks to its broad portfolio of medical devices, pharmaceuticals and consumer products – from band-aids and Rogaine to Tylenol for cancer relief and surgical sutures and medical implants – as well as its strong focus on women’s health initiatives and sponsorship of refugee families. Additionally, its philanthropic efforts include sponsoring refugee families while supporting women’s wellbeing.

J&J has made significant strides toward innovation with Accelerando over the last decade, employing global teams of statisticians in China, data managers in India and regulatory staff from Europe working around-the-clock to speed drugs from discovery to market faster. This model has successfully cut months or even years off drug development times.

This company has expanded its use of inclusive business models that meet the needs of patients in lower-income countries, such as releasing single dose Ebola vaccine at cost without profit-taking; and funding a low-cost primary healthcare center in Naivasha, Kenya that operates using a hub-and-spoke model.

Philanthropic activities by Johnson & Johnson and its support of female entrepreneurs and STEM education has cemented its reputation as a good corporate citizen. Through partnerships with FHI 360 and Junior Achievement to promote STEM programs for girls; as well as worldwide partnerships to increase undergraduate women registering as majors in science, technology, engineering and mathematics majors; Johnson & Johnson has cemented its position as one of the nation’s healthcare giants by encouraging innovation while cultivating an inclusive environment.

3. Creating a Focused Consumer Health Company

Johnson & Johnson stock was on an upswing that May morning and Analyst Day was upon us, giving CEO Alex Gorsky an opportunity to expand on an already big story.

J&J is the world’s largest health care conglomerate. With more than 250 operating companies – such as medical device, pharmaceutical, consumer health divisions with megabrands like Tylenol, Band-Aids, Rogaine – J&J products cover virtually every facet of life ranging from single-shot vaccines like Covid-19 to prosthetic legs and artificial joints.

Gorsky had been CEO of J&J’s pharmaceutical division for two years prior to becoming CEO of the entire company in March 2012. An adept insider, Gorsky took great advantage of his position to challenge many fundamental aspects of J&J’s business model that had previously been implemented.

After taking office, his top priority was revamping the company’s research and development operations. To facilitate this change, he introduced Accelerando: an intercontinental drug discovery team including statisticians in China, data managers in India and regulatory staff in Europe that collaborates around-the-clock on drug discovery efforts at Accelerando to speed the company’s drug discovery efforts – cutting months or years off timelines when new medicines reach market.

Techonomy recently spoke with Joaquin Duato, Johnson & Johnson’s head of pharmaceutical and consumer business units as well as its technology, supply chain, and sustainability initiatives. Duato spoke about how Johnson & Johnson has continued to reinvent itself amid the healthcare revolution sweeping through industry at hyperspeed; driving innovation at scale while managing digital transformation; as well as what he sees as being key challenges facing future healthcare.

4. Creating a Focused Pharmaceutical Company

J&J is one of the largest pharmaceutical companies worldwide and one of the best-known names in health and wellness. Well-known products from this multinational brand such as Band-Aids and Listerine reflect its 130 years of existence and provide proof of this strong pharmaceutical foundation.

New Jersey-based Medtronic was among the pioneers to mass produce sterile surgical supplies on an industrial scale and has since expanded into consumer health and pharmaceuticals. Their diverse business portfolio also features one of the world’s largest medical device businesses and divisions producing everything from contact lenses to tuberculosis medicines.

As J&J has grown and changed over time, its founding principles have remained intact. They drafted a 307-word corporate credo outlining their responsibilities to patients/physicians/employees/communities and shareholders – today every company decision must pass muster against this longstanding philosophy; J&J conducts “credo challenges”, similar to crisis drills; as well as biennial credo surveys to evaluate performance against their principles.

After the terrorist attacks of Sept. 11, 2001, J&J immediately responded with efforts to help heal our nation. Their supply centers stayed open around-the-clock so blood screening and typing supplies could reach hospitals that were struggling. J&J corporate aircraft even received “Angel Flight” status so they could deliver urgently needed supplies to military bases and civilian airports that had been closed off by providing “angel flights.”

Gorsky has long been an advocate of change at Johnson & Johnson. He worked to break down walls that had been put in place to maintain its integrity; also making key leadership changes including hiring Sandi Peterson as group worldwide chairman in 2012.

5. Creating a Focused Medical Device Company

Johnson & Johnson may be best known for its consumer health products like Band-Aids and baby shampoo, but the company also produces pharmaceuticals including antidepressants and cancer medications as well as medical devices like stents and orthopedic implants.

As soon as Gorsky took charge, investors were ready to dismiss J&J as an out-of-touch conglomerate. He made clear, however, that J&J’s broad base and diverse product offering are key components of its success – in fact he advocates strongly for what he terms the “diversified model.”

This company has devised an ingenious way of expediting drug development. Global teams–comprising statisticians in China, data managers in India, regulatory specialists from Europe–work around the clock to reduce time from development to market by months or even years. As a result, this company now boasts one of the fastest drug development processes in its field.

Johnson & Johnson not only has an efficient drug development process, but is also working hard to expand access to its medicines. One of the only major companies with a dedicated and measurable access strategy aiming for its pharmaceuticals to appear on the World Health Organization list of essential medicines.

J&J has long been dedicated to public health. Beginning in the early ’90s when AIDS infections were on the rise in industrialized nations and mother-to-child transmission was still a critical problem in developing nations, they made history by becoming one of the founding corporate donors to the Elizabeth Glaser Pediatric AIDS Foundation, helping it become the largest funder of HIV prevention and treatment programs worldwide.